Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis

Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2015, Pages 620-628

  Chen, Ping ^a   Melhem, Murad ^a   Xiao, Jim ^a   Kuchimanchi, Mita ^a   Perez Ruixo, Juan Jose ^a  

^a AMGEN INC   (United States)

Author keywords

AMG 416; calcium sensing receptor; NONMEM; pharmacokinetics; secondary hyperparathyroidism

Indexed keywords

CALCIUM; ETELCALCETIDE; PARATHYROID HORMONE; AMG-416; BIOLOGICAL MARKER; CALCIUM SENSING RECEPTOR; PEPTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; VOLUME OF DISTRIBUTION AT STEADY-STATE; AGONISTS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HYPERPARATHYROIDISM, SECONDARY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PEPTIDES; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928894382     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.460     Document Type: Article

References (20)

1. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Therap. 2004; 308 (2): 627-635.
2. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New England J Med. 2004; 350 (15): 1516-1525.
3. Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Therap. 2013; 346 (2): 229-240.
4. Shen J, Xiao J, Pickthorn K, et al. A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J Clin Pharmacol. 2014; 54 (10): 1125-1133.
5. Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dialysis Transplant. 2014; 29 (2): 385-392.
6. Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kid Int. 2014; 85 (1): 191-197.
7. Carroll RJRD,. Transformations and Weighting in Regression. New York: Chapman & Hall; 1988.
8. Savic R, Lavielle M,. Performance in population models for count data, part II: a new SAEM algorithm. J Pharmacokinet Pharmacodyn. 2009; 36 (4): 367-379.
9. Mandema JW, Verotta D, Sheiner LB,. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20 (5): 511-528.
10. Ette EI,. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997; 37 (6): 486-495.
11. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13 (2): 143-151.
12. Douglas C, Montgomery EAP,. Introduction to Linear Regression Analysis. NY: Wiley; 1982: 301-302.
13. Hooker AC, Staatz CE, Karlsson MO,. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharmaceut Res. 2007; 24 (12): 2187-2197.
14. Brendel K, Comets E, Laffont C, Laveille C, Mentre F,. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharmaceut Res. 2006; 23 (9): 2036-2049.
15. Tang LMB,. Pharmacokinetics of peptides and proteins. In:, Meibohm B, ed. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Wiley-VCH; 2006: 15-43.
16. Lin JH,. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metabol. 2009; 10 (7): 661-691.
17. Migdalof BH, Antonaccio MJ, McKinstry DN, et al. Captopril: pharmacology, metabolism and disposition. Drug Metabol Rev. 1984; 15 (4): 841-869.
18. Perrett D,. The metabolism and pharmacology of D-penicillamine in man. J Rheumatol Suppl. 1981; 7: 41-50.
19. He YL, Murby S, Gifford L, et al. Oral absorption of D-oligopeptides in rats via the paracellular route. Pharmaceut Res. 1996; 13 (11): 1673-1678.
20. Hong SY, Oh JE, Lee KH,. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol. 1999; 58 (11): 1775-1780.